Liang Chen, Yang Jing-Bo, Lin Xin-Yi, Xie Bi-Lan, Xu Yun-Xian, Lin Shu, Xu Tian-Wen
Department of Digestive Tumours, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Centre of Neurological and Metabolic Research, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
Front Oncol. 2022 Oct 13;12:911856. doi: 10.3389/fonc.2022.911856. eCollection 2022.
Colorectal cancer (CRC) is the third most common malignancy in the world and one of the leading causes of cancer death; its incidence is still increasing in most countries. The early diagnostic accuracy of CRC is low, and the metastasis rate is high, resulting in a low survival rate of advanced patients. MicroRNAs (miRNAs) are a small class of noncoding RNAs that can inhibit mRNA translation and trigger mRNA degradation, and can affect a variety of cellular and molecular targets. Numerous studies have shown that miRNAs are related to tumour progression, immune system activity, anticancer drug resistance, and the tumour microenvironment. Dysregulation of miRNAs occurs in a variety of malignancies, including CRC. In this review, we summarize the recent research progress of miRNAs, their roles in tumour progression and metastasis, and their clinical value as potential biomarkers or therapeutic targets for CRC. Furthermore, we combined the roles of miRNAs in tumorigenesis and development with the therapeutic strategies of CRC patients, which will provide new ideas for the diagnosis and treatment of CRC.
结直肠癌(CRC)是全球第三大常见恶性肿瘤,也是癌症死亡的主要原因之一;在大多数国家,其发病率仍在上升。CRC的早期诊断准确率较低,转移率较高,导致晚期患者生存率较低。微小RNA(miRNA)是一类小的非编码RNA,可抑制mRNA翻译并触发mRNA降解,并能影响多种细胞和分子靶点。大量研究表明,miRNA与肿瘤进展、免疫系统活性、抗癌药物耐药性以及肿瘤微环境有关。miRNA的失调发生在包括CRC在内的多种恶性肿瘤中。在本综述中,我们总结了miRNA的最新研究进展、它们在肿瘤进展和转移中的作用,以及它们作为CRC潜在生物标志物或治疗靶点的临床价值。此外,我们将miRNA在肿瘤发生和发展中的作用与CRC患者的治疗策略相结合,这将为CRC的诊断和治疗提供新思路。